{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-016497","form_type":"8-K","ticker":"ABT","cik":"0000001800","company_name":"ABBOTT LABORATORIES","filed_at":"2024-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.180141+00:00","generated_at":"2026-06-03T21:46:15.115939+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Abbott Q1 adj. EPS $0.98; raises FY2024 midpoint guidance","bullets":["Q1 GAAP diluted EPS $0.70; adjusted diluted EPS $0.98; revenue $9.96B (+2.2% reported).","Organic base business sales grew 10.8% YoY; fifth consecutive double-digit quarter.","FY2024 adjusted EPS guidance raised to $4.55-$4.70 midpoint; organic sales growth 8.5%-10.0% ex-COVID tests.","Medical Devices organic sales +14.3%; FreeStyle Libre revenue $1.5B (+22.4% reported).","FDA approved TriClip for tricuspid regurgitation and i-STAT TBI test; quarterly dividend $0.55/share maintained."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-016497","json":"https://secwatch.observer/filing/0001628280-24-016497.json","markdown":"https://secwatch.observer/filing/0001628280-24-016497.md","text":"https://secwatch.observer/filing/0001628280-24-016497.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800/000162828024016497/0001628280-24-016497-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800/000162828024016497/abt-20240417.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T21:46:15.115939+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"363ebc874444fa0e298452202d8bc7a2323e828c","claim":"ABBOTT LABORATORIES reported the first quarter ended March 31, 2024 results: revenue $10.0 billion, EPS $0.70. Guidance raised.","evidence_excerpt":"Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges – Sales of $10.0 billion driven by strong underlying base business performance – Reported sales increased 2.2 percent, which includes the impact from the anticipated decline in COVID-19 testing-related sales versus prior year – Organic sales growth for underlying base business of 10.8 percent, which represents the fifth consecutive quarter of double-digit growth 1 ABBOTT PARK, Ill., April 17, 2024 — Abbott today announced financial results for the first quarter ended March 31, 2024. • First-quarter GAAP diluted EPS of $0.70 and adjusted diluted EPS of $0.98, which excludes specified items.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828024016497/0001628280-24-016497-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$10.0 billion"},{"label":"EPS","value":"$0.70"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}